Fig. 6: Breast cancer molecular subtype shifts between baseline, cycle 2 day 1 and surgery paired samples. | npj Breast Cancer

Fig. 6: Breast cancer molecular subtype shifts between baseline, cycle 2 day 1 and surgery paired samples.

From: Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Fig. 6

a Hormone receptor positives tumors. b Triple-negative tumors, c Variation of PAM50-based, claudin-low and hypoxia signatures between baseline, Cycle 2 Day 1 (C2D1) and surgery in hormone receptor-positive and triple-negative breast cancer. Error bars correspond to standard error of the mean.

Back to article page